IMF-001

N/A

Report date: 2022/04/18 17:53:04

Base Information

Drug NameIMF-001

Drug Alias Name靶向肿瘤/睾丸抗原-1重组蛋白疫苗(Immunofrontier)CHP-NY-ESO-1IMF-001

ClassificationVaccines > Development/production technology > Genetically engineered subunit vaccineVaccines > Application > Therapeutic vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsEsophageal adenocarcinomaProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesImmunofrontier Inc

China Registration ClassN/A

Active CompaniesN/A

Active IndicationsN/A

Inactive IndicationsEsophageal adenocarcinomaProstatic Neoplasms

ATC CodeN/A